Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest
Clinical trials sponsored by Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Experimental cancer combo aims to supercharge immune attack on tumors Results expected Sep 2026 (estimated)
- Double immunotherapy combo aims to boost lung cancer surgery outcomes Results expected Dec 2026 (estimated)
- New cocktail targets HER2-Positive bile duct cancer in small trial Results expected Dec 2026 (estimated)
- Aiming to cure esophageal cancer without the knife Results expected Jan 2027 (estimated)
- Heat and immunotherapy join forces against bile duct cancer Results expected Jan 2027 (estimated)
-
Double immune attack: new combo aims to boost CAR-T success in tough lymphoma
Disease control Not yet recruitingThis phase 2 trial tests whether adding a drug called glofitamab before and after standard CAR-T cell therapy can improve outcomes for 20 adults with high-risk, relapsed or refractory large B-cell lymphoma. Participants first receive glofitamab with chemotherapy, then CAR-T cells…
Phase 2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New Pre-Surgery combo aims to boost cancer fight in stomach and esophageal tumors
Disease control Not yet recruitingThis study tests giving a combination of chemotherapy (FLOT) and an immunotherapy drug (durvalumab) before surgery, followed by more durvalumab after surgery, for people with stomach or esophageal cancer that can be removed. The goal is to see if this approach leads to a complete…
Phase 2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC